Immunology Investor Event
Amlitelimab - Priority Asset with a
highly competitive target profile
Ph 2 study¹: >40% with clear/almost
clear skin (16 weeks Q4W)
60
***
50
44.4
40
40
37
10
Proportion of VIGA 0/1
10
20
patients, %
20
30
30
0
amlitelimab
low dose
(n=27)
***
8.3
amlitelimab
high dose.
(n=27)
Placebo
(n=24)
Potential first-in-class anti-OX40L
Convenient subcutaneous administration
starting with Phase 2b
Attractive target product profile due to
infrequent dosing regimen and durability of
response, addressing mixed-phenotype
AD populations
sanofi
Ph 2 study²: AMG451 (16 weeks Q2W)
Proportion of VIGA 0/1
patients, %
60
50
40
30.8
30
20
20
10
10
**
18.5
1.8
0
AMG451
300mg
AMG451
600mg
Placebo
~70% of IGA 0/1 patients with sustained response off drug for 24 weeks
***p<0.001 vs placebo (Cochran-Mantel-Haenszel test)
1. Abstract 2729, Weidinger S, EADV 2021
The information on this slide is for purposes of illustrating amlitelimab's differentiated target profile. No head to head studies have been conducted and therefore, no
conclusions should be drawn regarding the clinical efficacy of amlitelimab alone or in comparison to any investigational or approved treatment.
33 Immunology Investor Event
**p<0.001; *p<0.05 vs placebo (Cochran-Mantel-Haenszel test)
2. Abstract 2867, Guttman-Yassky E, EADV 2021View entire presentation